Cathepsin B Protein (CTSB) (AA 18-339)

Produktnummer ABIN2666495

Dieses Recombinant Cathepsin B-Protein wird in HEK-293 Cells exprimiert.

Kurzübersicht für Cathepsin B Protein (CTSB) (AA 18-339) (ABIN2666495)

Target: Cathepsin B (CTSB)

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Applikation: Flow Cytometry (FACS)

Reinheit: > 95 % , as determined by Coomassie stained SDS-PAGE under reducing conditions

Produktdetails

Proteineigenschaft: AA 18-339

Sterilität: 0.22 μm filtered

Endotoxin-Niveau:

Less than 0.01ng per μg cytokine, as determined by the LAL method.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Biological activity: The activity of CTSB is determined by its ability to cleave the fluorogenic peptide substrate, Z-Leu-Arg-AMC (Z=Benzyloxycarbonyl, AMC=7-amino-4-methylcoumarin) after stimulation. The specific activity is >2,500 pmol/min/μg.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Rekonstitution: For maximum results, quick spin vial prior to opening.

Buffer: 0.22μm filtered protein solution is in 20 mM Tris, 100 mM NaCl, and pH 8.0.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Unopened vial can be stored at -70°C for six months.

Antigendetails

Target: Cathepsin B (CTSB)

Andere Bezeichnung: Cathepsin B

Hintergrund: Cathepsin B (CTSB) is a lysosomal cysteine protease. While most cathepsins are exclusively endopeptidases, CTSB exhibits both carboxypeptidase and endopeptidase activities. The optimal pH for CTSB activity is between four and six. Cystatin C has been identified as an endogenous CTSB inhibitor. High CTSB protein levels and activities have been found in many tumors including breast, cervix, colon, stomach, glioma, lung and thyroid tumors. CTSB can be secreted by tumor cells and is associated with the cell membrane of these cells. Membrane associated CTSB promotes extracellular matrix (ECM) degradation contributing to cancer motility and invasion. Many ECM proteins, including laminin, fibronectin, and collagen IV, are substrates of CTSB. CTSB can also activate pro-uPA/PLAU. Activated uPA promotes ECM digestion through serine protease plasminogen. It has been shown that the inhibition of CTSB can limit bone metastasis in breast cancer, making it an important anti-cancer drug target. CTSB has been proposed as a new drug target for Alzheimer's disease because of its involvement in the production of neurotoxic β -amyloid (Aβ) peptides. The inhibition of CTSB can reduce the brain Aβ peptides and improve memory determined from a mouse model with Alzheimer's disease. CTSB also plays significant roles in immune responses including both T and B cell apoptosis and Th1/Th2 polarization. CTSB is implicated in other pathological conditions including cardiovascular disease, multiple sclerosis, and arthritis. Roles of CTSB in autophagy, adipogenesis, and cholesterol absorption in the intestine have also been studied.

Molekulargewicht: The 332 amino acid recombinant protein has a predicted molecular mass of approximately 37 kDa. The DTT-reduced and non-reduced protein migrate at approximately 45 kDa by SDS-PAGE. The predicted N-terminal amino acid is Arg.

Pathways: Activation of Innate immune Response, Toll-Like Receptors Cascades